{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:57:51Z","timestamp":1790258271955,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.bulcan.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T00:31:37Z","timestamp":1491438697000},"page":"552-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices"],"prefix":"10.1016","volume":"104","author":[{"given":"Anthony","family":"Turpin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Berdah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2017.02.002_bib0095","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Loriot","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0115","unstructured":"NCCN guidelines Prostate Cancer, Version 1.2016.11\/10\/15\u00a9 National Comprehensive Cancer Network, Inc 2015. All right reserved. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.bulcan.2017.02.002_bib0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0125","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(15)70033-1","article-title":"Sequencing of agents in castration-resistant prostate cancer","volume":"16","author":"Lorente","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0130","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0135","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","author":"Cornford","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0140","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.eururo.2013.08.007","article-title":"Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study","volume":"66","author":"Van Soest","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2015.07.011","article-title":"Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer","volume":"100","author":"Maroto","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0150","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","article-title":"Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer","volume":"21","author":"Halabi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0155","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejca.2009.11.007","article-title":"The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival","volume":"46","author":"Armstrong","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.eururo.2005.11.032","article-title":"Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer","volume":"49","author":"Svatek","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0165","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.urology.2009.11.049","article-title":"Implications of serum bone turnover markers in prostate cancer patients with bone metastasis","volume":"75","author":"Kamiya","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cncr.24064","article-title":"Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy","volume":"115","author":"Choueiri","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0175","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2017.02.002_bib0180","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mdv594","article-title":"A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel","volume":"27","author":"Chi","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117300565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455117300565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T23:21:46Z","timestamp":1535930506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455117300565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0007455117300565"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.02.002","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}